New schizophrenia drug tested for Long-Term safety in 500 patients

NCT ID NCT07459647

First seen Mar 21, 2026 · Last updated May 12, 2026 · Updated 9 times

Summary

This study is testing the long-term safety and effectiveness of an investigational drug called ML-007C-MA in adults with schizophrenia. About 500 participants will take the drug for up to 52 weeks to see how well it is tolerated and if it helps control symptoms. The goal is to find a treatment that can be used safely over a long period.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Site

    RECRUITING

    Lemon Grove, California, 91945, United States

  • Clinical Site

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • Clinical Site

    RECRUITING

    Chicago, Illinois, 60640, United States

  • Clinical Site

    RECRUITING

    Staten Island, New York, 10314, United States

  • Clinical Site

    RECRUITING

    DeSoto, Texas, 75115, United States

Conditions

Explore the condition pages connected to this study.